Panelists discuss strategies for simplifying complex information for primary care physicians (PCPs), provide tips on how PCPs can effectively communicate evidence-based treatment options to patients, and outline actionable points and key takeaways to enhance patient care in managing menopause symptoms.
The coverage with evidence development (CED) policy requires enrollment in an active clinical trial for an adult to be eligible for Medicare coverage of treatment for Alzheimer's disease.
A concise update on legal status, FDA approvals, patient safety, and public perception.
Investigators identified 6 blood pressure patterns that, when combined with other risk factors, accurately stratified risk of hypertensive disorders of pregnancy.
Experts wrap up their discussion of emerging chronic kidney disease tests and treatments with key takeaways for providers and patients.
A panelist discusses how simplifying treatment regimens, using nonsteroidal options, and fostering collaboration between primary care and dermatology can improve patient adherence and outcomes while emphasizing the importance of careful consideration when transitioning to systemic treatments or biologics due to safety concerns and patient needs.
Panelists discuss how choosing topical treatments requires individualized therapy considering factors such as affected body areas, disease severity, patient age, formulation preferences, and insurance coverage.
Beginning on Sept 24, 2024, all women must be notified of their breast density status in mammography reports and encouraged to pursue supplemental screening.
Only about 75% of people with a positive result on a stool-based test for colorectal cancer complete screening with a colonoscopy. Fendrick "won't rest" until it's 90%.
Biosimilars Wyost and Jubobonti were approved as interchangeable for Xgeva and Prolia but launch will depend on the outcome of litigation between reference product manufacturers.
In an interview at AAD 2025, Katrina Abuabara, MD, stressed the importance of collaboration between primary care physicians and dermatologists.
A panelist discusses how education about anaphylaxis recognition, early epinephrine administration, and addressing barriers like device portability remains crucial, with intranasal epinephrine potentially solving many existing challenges in anaphylaxis management.
The only pre-exposure prophylaxis approved for twice-a-year dosing, lenacapavir "could be the transformative PrEP option we’ve been waiting for," one expert said.
Peer mentor programs can provide support for patients, especially when it comes to family planning and parenthood.
The diagnostic is designed to help clinicians determine the likelihood of cerebral β-amyloid plaque deposition, one of the neuropathologic hallmarks of AD.
Health care leaders increasingly are looking to technology for solutions to the challenges facing primary care.
Experts on diabetes provide insights gleaned from the SIMPLE study and outline patient factors that inform treatment decisions.
How current are you on CAC and its place in CVD risk assessment? This short quiz will reveal your score.
Experts discuss the efficacy of the latest vaccines against currently circulating strains of COVID-19, commenting on how long immunity lasts from these vaccines.
RAD 2025: Multidisciplinary collaboration at disease-specific meetings drives clinical and therapeutic progress in AD, Dr Yu told Patient Care.
Rates of amputation in Black Americans with peripheral arterial disease are 3-times higher than that of their White counterparts. Dr Fakorede, discusses, here.
William Schaffner, MD, advises first and foremost to stay away from politics, to acknowledge and normalize patient fear and concern, and to answer quickly and with confidence.
Panelists discuss how providers should actively screen for vasomotor symptoms (VMS), especially given the lengthy wait times to see specialists, emphasizing that education for both patients and health care providers is essential for timely intervention and effective management.
WHO: Evidence is lacking for clinical effectiveness of Xevudy and Regen-Cov against the COVID-19 variants that are currently circulating.
The panel concludes its discussion with key takeaways on the optimal care of patients with type 1 diabetes care and thoughts on unmet needs within the treatment space.
Panelists discuss how real-world patient cases demonstrate the importance of individualizing obstructive sleep apnea treatment plans by considering factors such as disease severity, comorbidities, lifestyle, and patient preferences to optimize outcomes.